News Releases

June 30, 2015

RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis
ReaCT Trial at University of British Columbia Treating Patients with Autologous Cell Therapy VANCOUVER, BC – June 30, 2015 – RepliCel Life Sciences Inc.... Read full article

June 26, 2015

RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – June 26, 2015 – RepliCel... Read full article

June 5, 2015

RepliCel Life Sciences Announces Participation in 23rd World Congress of Dermatology, Vancouver, BC
Conference program to include presentations on the clinical development of RepliCel’s skin rejuvenation, hair regeneration, and tendon repair technologies VANCOUVER, BC – June 5,... Read full article

June 1, 2015

RepliCel Life Sciences Announces Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – June 1, 2015 – RepliCel... Read full article

May 20, 2015

RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference
Clinical trial at the University of British Columbia now recruiting patients VANCOUVER, BC – May 21, 2015 – RepliCel Life Sciences Inc. (TSX.V: RP)... Read full article

May 7, 2015

RepliCel Life Sciences Selected to Present at Cavendish Global Health Impact Forum
Unique forum brings together leading family offices and foundations seeking impactful investment and philanthropic opportunities within healthcare and life sciences VANCOUVER, BC –  May... Read full article

April 29, 2015

RepliCel Announces 2014 Fourth Quarter and Year-End Financial Results
VANCOUVER, BC – April 29, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the... Read full article

April 15, 2015

RepliCel Life Sciences Receives Approval to Conduct Clinical Trial for Patients with Chronic Achilles Tendinosis
The University of British Columbia Clinical Research Ethics Board Clears Clinical Trial to Proceed with Site Initiation and Patient Recruitment VANCOUVER, BC – April... Read full article

April 7, 2015

RepliCel Life Sciences Receives TSX Venture Exchange Approval to Extend Warrant Expiry Dates
VANCOUVER, BC – April 7, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine... Read full article

April 2, 2015

RepliCel Life Sciences Applies to Extend Warrant Expiry Dates
VANCOUVER, BC – April 2, 2015 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine... Read full article